CML Publications of the Month
As part of our monthly news service we would like to make you aware of important CML publications. From the many papers published in April, Professor Jerry Radich has selected topical, interesting papers for your perusal. Papers with a clinical, scientific, pediatric and low and middle income country focus are shared.
April 2026
Clinical CML papers
Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of EBMT
Kanellopoulos A et al. Bone Marrow Transplant, April 2026 (epub ahead of print)
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors
Hochhaus A et al. Leukemia, April 2026 – open access publication
Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study
Breccia M et al. Ann Hematol, April 2026 – open access publication
A current overview of quality of life research in chronic myeloid leukemia (CML)
Deneberg S et al. Cancers (Basel), April 2026 – open access publication
Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia
Yolcu A and Haznedaroglu IC. Expert Rev Hematol, April 2026 (epub ahead of print)
The care and cure of the leukemias in 2026
Kantarjian H et al. Am J Hematol, April 2026
Patients’ and healthcare providers’ views regarding dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: a qualitative study
Lokhorst DN et al. Oncologist, April 2026 – open access publication
A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia
Basabrain, A.A.et al. Int. J Mol Sci, March 2026
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes
Gagnon, L.L. et al. Leukemia, March 2026 – open access publication
Scientific CML papers
Targeting the BCR::ABL1 kinase: Advances beyond imatinib in chronic myeloid leukemia
Naderi Z et al. Curr Hematol Malig Rep, April 2026
Targeting STAT5 via CRISP/Cas9 restores TKI sensitivity in resistant CML cells
Çelik B et al. Med Oncol, April 2026 – open access publication
Understanding drug resistance in chronic myeloid leukemia through the lens of leukemia stem cell states: insights from single-cell analyses
Krishnan V et al. Haematologica, April 2026 (epub ahead of print) – open access publication
An AI-enabled single-cell transcriptomic analysis pipeline for gene signature discovery in natural killer cells linked to remission outcomes in chronic myeloid leukemia
Borra S et al. Biology (Basel), April 2026 – open access publication
Pediatric CML papers
Prevalance and characterization of germline RAS pathway variants in children with chronic myeloid leukemia
Ghete T et al. Leukemia, April 2026 (epub ahead of print) – open access publication
LMIC CML papers
Genetic and non-genetic correlates of imatinib pharmacokinetics and side effects of imatinib in Palestinian patients with chronic myeloid leukemia
Adawi DH et al. Biochem Genet, April 2026
Breaking barriers: Reducing cost and overcoming challenges in BCR::ABL1 monitoring for chronic myeloid leukemia in Brazil
Etges APBDS et al. JCO Glob Oncol, April 2026 - open access publication
CML and COVID-19
Immune response to SARS-CoV-2 vaccination among chronic myeloid leukemia patients on tyrosine kinase inhibitors
Cheong CS et al. Ann Acad Med Singap, April 2026 (epub ahead of print) – open access publication